Cipla Limited announced its unaudited consolidated financial results for quarter ended December 31st, 2022.

Revenue growth for the quarter was at 6% YoY on a reported basis and a strong 11% YoY ex-covid.

The company posted Robust double-digit traction in core portfolio across therapies and business segments; 11% YoY ex-covid growth.

R&D investments stands at Rs. 363 crores or 6.2 % of sales.